Mezigdomide

• Phase 1b/2a Study to Evaluate Alnuctamab in Combination with Mezigdomide in Relapsed and/or Refractory Multiple Myeloma. Not authorised
  2023-504367-16-00 Phase II 1 country Celgene International II S.a.r.l.
• A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed mult… Pending
  2025-520976-25-00 Phase II 1 country Centre Hospitalier Universitaire De Saint Etienne
• A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refrac… Pending
  2025-521090-14-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma Recruiting
  2025-522090-11-00 Phase I/II 4 countries Celgene Corp.
• Phase 1b/2a Study to Evaluate CC-92480 (BMS-986348) in Combination with Other Treatments in Relapsed or Refractory Multiple Myeloma Recruiting
  2023-509384-25-00 Phase I/II 2 countries Celgene Corp.
• Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult… Ended
  2022-500861-29-00 Phase III 11 countries Celgene Corp.
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended
  2023-509859-13-00 Phase III 13 countries Celgene Corp.
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel… Ended
  2023-505219-19-00 Phase I/II 6 countries Celgene Corp.
• A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not R… Ended
  2023-508727-12-00 Phase II 2 countries Celgene Corp.

Showing 1–9 of 9 trials